跳至主要内容
临床试验/NCT00190060
NCT00190060
已完成
4 期

Study of The Effects of Testosterone on Muscle Function, Physical Performance, Body Composition and Quality of Life in Frail Elderly Men

Manchester University NHS Foundation Trust1 个研究点 分布在 1 个国家目标入组 262 人2004年10月

概览

阶段
4 期
干预措施
Transdermal testosterone gel (Testogel 1% )
疾病 / 适应症
Frailty
发起方
Manchester University NHS Foundation Trust
入组人数
262
试验地点
1
主要终点
Lower limb muscle strength at 6 months
状态
已完成
最后更新
7年前

概览

简要总结

The study aims to determine the effects of testosterone on muscle function, mobility, activities of daily living and overall quality of life

详细描述

Ageing-associated loss of muscle mass and strength is a major cause of physical frailty, disability, morbidity and dependency in the elderly. This is associated with increased falls, fractures, loss of mobility, restricted activities of daily living and increased utilisation of healthcare resources. It is well known that serum testosterone levels fall with advancing age and this may be an important cause for muscle wasting and weakness (sarcopenia). Testosterone replacement increases muscle mass and improves muscle strength in young hypogonadal men. In relatively healthy elderly men, some short-term studies have also shown that testosterone can improve muscle strength. The potential beneficial effects of testosterone supplementation on muscle strength and functional capacity of frail elderly men has so far not been studies and forms the basis of this research. We hypothesise that testosterone supplementation is an effective, safe and economic anabolic intervention in frail elderly men with low circulating testosterone.

注册库
clinicaltrials.gov
开始日期
2004年10月
结束日期
2008年12月31日
最后更新
7年前
研究类型
Interventional
研究设计
Parallel
性别
Male

研究者

入排标准

入选标准

  • Frail elderly men (as defined by Freid's criteria of frailty)
  • Community - dwelling men aged 65 years and above
  • Total testosterone ≤12.0 nmol/L or calculated free T≤0.25nmol/L

排除标准

  • Carcinoma of prostate
  • Carcinoma of breast
  • PSA \>4ng/mL
  • Severe symptomatic benign prostatic hypertrophy (IPSS \>21)
  • Active liver disease
  • Renal impairment (serum creatinine \>180 mmol/L)
  • Congestive heart failure
  • Unstable ischaemic heart disease
  • Polycythaemia
  • Evidence of systemic disease which may affect muscle/joint function

研究组 & 干预措施

1

Transdermal testosterone gel (Testogel 1% )

干预措施: Transdermal testosterone gel (Testogel 1% )

2

Matched transdermal placebo gel

干预措施: Matched transdermal placebo gel

结局指标

主要结局

Lower limb muscle strength at 6 months

时间窗: 6 months

次要结局

  • Upper limb muscle strength at 6 months(6 months)
  • Improvement in physical performance(6 months)
  • Bone Mineral Density(6 months)
  • Quality of life at 6 months(6 months)
  • Total and regional lean body mass at 6 months(6 months)

研究点 (1)

Loading locations...

相似试验